Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
Clinical trial NCT04807595 · COMPLETED
Trial details
- NCT number
- NCT04807595
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-05-28
- Primary completion
- 2022-04-26
- Enrollment
- 798
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.